Celldex Announces Proposed Public Offering of Common Stock to Fund Ongoing Activities and Development

Celldex Therapeutics has announced a proposed public offering of common stock, with the intention of using the proceeds to fund commercial readiness activities, product candidate development, and general corporate purposes. The offering is being managed by Leerink Partners and TD Cowen, and the final terms will depend on market conditions.